13 research outputs found
Immune Potentiation of PLGA Controlled-Release Vaccines for Improved Immunological Outcomes
Epidemiology of surgery associated acute kidney injury (EPIS-AKI): a prospective international observational multi-center clinical study
Immune Potentiation of PLGA Controlled-Release Vaccines for Improved Immunological Outcomes
With the emergence
of SARS-CoV-2 and the continued emergence
of
new infectious diseases, there is a need to improve and expand current
vaccine technology. Controlled-release subunit vaccines provide several
benefits over current vaccines on the market, including the use of
less antigen and fewer boost doses. Previously, our group reported
molecules that alter NF-ÎșB signaling improved the vaccineâs
performance and improved adjuvant-related tolerability. In this report,
we test how these immune potentiators will influence responses when
included as part of a controlled-release poly(lactic-co-glycolic) vaccine formulation. Murine in vivo studies revealed that
SN50 and honokiol improved antibody levels at early vaccine time points.
Microparticles with SN50 produced strong antibody levels over a longer
period compared to microparticles without SN50. The same particles
also increased T-cell activity. All of the immune potentiators tested
further promoted Th2 humoral responses already exhibited by the control
CpG OVA microparticle formulation. Overall, under controlled-release
conditions, immune potentiators enhance the existing effects of controlled-release
formulations, making it a potentially beneficial additive for controlled-release
vaccine formulations
Ecology of Potential West Nile Virus Vectors in Southeastern Louisiana: Enzootic Transmission in the Relative Absence of Culex quinquefasciatus
Vaginal Reconstruction Following Radical Surgery for Colorectal Malignancies: A Systematic Review of the Literature
How well do you know your mutation? Complex effects of genetic background on expressivity, complementation, and ordering of allelic effects
Role of Palliative Care in the Outpatient Management of the Chronic Heart Failure Patient
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Neoantigens, which are derived from tumour-specific protein-coding mutations, are exempt from central tolerance, can generate robust immune responses1,2 and can function as bona fide antigens that facilitate tumour rejection3. Here we demonstrate that a strategy that uses multi-epitope, personalized neoantigen vaccination, which has previously been tested in patients with high-risk melanoma4â6, is feasible for tumours such as glioblastoma, which typically have a relatively low mutation load1,7 and an immunologically âcoldâ tumour microenvironment8. We used personalized neoantigen-targeting vaccines to immunize patients newly diagnosed with glioblastoma following surgical resection and conventional radiotherapy in a phase I/Ib study. Patients who did not receive dexamethasoneâa highly potent corticosteroid that is frequently prescribed to treat cerebral oedema in patients with glioblastomaâgenerated circulating polyfunctional neoantigen-specific CD4+ and CD8+ T cell responses that were enriched in a memory phenotype and showed an increase in the number of tumour-infiltrating T cells. Using single-cell T cell receptor analysis, we provide evidence that neoantigen-specific T cells from the peripheral blood can migrate into an intracranial glioblastoma tumour. Neoantigen-targeting vaccines thus have the potential to favourably alter the immune milieu of glioblastoma